Associate Clinical Data Scientist

Zita Moghadam

Who We Are
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

What We Do
We aim to bring differentiated, high-quality, and needed healthcare products to as many people as possible

How We Do It
Our teams are focused on our 3 long-term priorities:
Innovation, Performance, Trust

GlaxoSmithKline – Three global businesses; Pharmaceuticals, Vaccines and Consumer Healthcare

Pharmaceuticals – Contains a broad portfolio of innovative and established medicines

Research & Development – Creates our pipeline with a focus on science related to the immune system, human genetics and advanced technologies

Global Clinical Operations – Runs clinical trials to establish efficacy and safety of medicines

Global Clinical Data Operations – Oversees all aspects of data collection and management in clinical trials

Data Management – Ensure all data collected in our trials is complete and of high quality

Infectious Diseases – Therapy area; includes portfolios of treatments for HIV, malaria, and antibiotics





Clinical Studies

Activities detailed in the diagram to the left were completed for all four studies described below, and for some studies yet to be launched. Portfolio level oversight work was also completed to streamline Data Management activities across the programme.

FLAIR – First Long Acting Injectable Regimen

To establish if HIV-1 infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen will remain suppressed after switching to a two drug intramuscular long-acting (LA) regimen of **cabotegravir** (CAB) and **rilpivirine** (RPV).

ATLAS – Antiretroviral Therapy as Long Acting Suppression

To establish if HIV-1 infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular LA regimen of CAB and RPV.

ATLAS 2M – Antiretroviral Therapy as Long Acting Suppression every 2 Months

To demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every 8 weeks compared to CAB LA + RPV LA administered every 4 weeks over a 48-week treatment period in approximately 1020 adult HIV-1 infected subjects.

CUSTOMIZE – Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience

To identify and evaluate approaches to implementing a once-monthly, injectable treatment for HIV into clinical practice.

Extra-Curricular Activities

I joined the Trailblazer group for the Clinical Trials Specialist Degree Apprenticeship. This involved supporting the development of our apprentices, and designing their end of programme assessment.

As a STEM ambassador I visited local schools to conduct workshops and inspire the next generation of scientists. I also Project Managed a five-day insight week at GSK, teaching students the journey of medicines from Molecule to Market.

As IP Unite Vice Chair and site ambassador, I represented all students in my business area to the company. I facilitated UK wide communications, organised a number of charity events and a nationwide Development Day.

All students at my site met each month to discuss a GSK publication. We critically evaluated clinical techniques to better understand the Clinical Trial process.

I received a Platinum Industrial Cadets award in recognition of my skills and behaviours developed on my Industrial Placement.



Acknowledgements & References

This year would not have been possible without the support and guidance given by my manager, Sandy Pinto, or mentoring and extra-curricular support from Oyiza Momoh and Carmelene Godwin.

About us [Online]. GlaxoSmithKline. Available from: https://www.gsk.com/en-gb/about-us/ [20 May 2020].

February 18, 2020. *Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir + Rilpivirine in the United States (US)* [Online]. NIH, U.S. Department of Health and Human Services. Available from: *https://www.clinicaltrials.gov/ct2/show/NCT04001803* [02 May 2020].

June 11, 2020. *Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults* [Online]. NIH, U.S. Department of Health and Human Services. Available from: https://clinicaltrials.gov/ct2/show/NCT03299049 [14 June 2020].

March 17, 2020. *Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults* [Online]. NIH, U.S. Department of Health and Human Services. Available from: *https://www.clinicaltrials.gov/ct2/show/NCT02951052* [02 May 2020].

March 23, 2020. *Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants* [Online]. NIH, U.S. Department of Health and Human Services. Available from: *https://clinicaltrials.gov/ct2/show/NCT02938520* [2 May 2020].